Healthcare


 Monash IVF (ASX:MVF) Attracts Market Buzz Despite Recent Setback

Monash IVF (ASX:MVF) Attracts Market Buzz Despite Recent Setback

July 08, 2025 04:49 PM AEST| By Team Kalkine Media

Highlights,Monash IVF (MVF) under focus after operational mishap,Adjusted financial outlook reflects anticipated market share shifts,Sector valuation hints at consolidation prospects,Monash IVF (ASX:MVF), a prominent name in Australia’s fertility ser...

 CSL (ASX:CSL) Share Price Under Watch: Exploring the Resilience of a Leading Healthcare Stock in the ASX 300 Index

CSL (ASX:CSL) Share Price Under Watch: Exploring the Resilience of a Leading Healthcare Stock in the ASX 300 Index

July 07, 2025 06:29 PM AEST| By Team Kalkine Media

Highlights,CSL operates across plasma, flu vaccine, and renal care segments,Part of the ASX 300 Index, reflecting its position among Australia’s largest listed entities,Healthcare demand continues to show global momentum,CSL Ltd (ASX:CSL) remains a p...

 Nanosonics (ASX:NAN) Elevates Infection Prevention with trophon3 Launch

Nanosonics (ASX:NAN) Elevates Infection Prevention with trophon3 Launch

July 07, 2025 04:46 PM AEST| By Team Kalkine Media

Highlights,Nanosonics unveils trophon3 with faster disinfection and digital integration,trophon2 Plus software upgrade brings advanced features to existing systems,Launch extends across multiple regions; FDA review in progress,Nanosonics (ASX:NAN), a...

 CSL Ltd (ASX:CSL) Strengthens Healthcare Footprint in ASX Top 300

CSL Ltd (ASX:CSL) Strengthens Healthcare Footprint in ASX Top 300

July 04, 2025 07:41 PM AEST| By Team Kalkine Media

Highlights,CSL Ltd is a key healthcare company in the ASX Top 300 and ASX 100,Business operations include plasma therapies, flu vaccines, and kidney treatments,Regular payouts place CSL under asx dividend stocks,CSL Ltd (ASX:CSL) is listed under the,...

 Orthocell's Remplir Drives Record Quarterly Revenue Surge on Expanding Hospital Adoption

Orthocell's Remplir Drives Record Quarterly Revenue Surge on Expanding Hospital Adoption

July 04, 2025 03:13 PM AEST| By Team Kalkine Media

Highlights,Record A$2.73 million quarterly revenue,Over 206 surgeons now using Remplir in 166+ hospitals,US expansion set to accelerate future momentum,Orthocell Ltd (ASX:OCC) has reported a record-breaking revenue performance for the June 2025 quart...

 ASX 200 Health Sector Lags but Amplia and Biotech Peers Shine in June

ASX 200 Health Sector Lags but Amplia and Biotech Peers Shine in June

July 04, 2025 02:16 PM AEST| By Team Kalkine Media

Highlights,ASX 200 Health Care sector underperforms broader index despite isolated stock rallies,Amplia Therapeutics records complete cancer responses in ACCENT trial,Neuro and radiopharma companies advance on clinical updates and acquisitions,The,AS...

 Imugene Advances Cancer Trials with Fresh Funding and Clinical Progress

Imugene Advances Cancer Trials with Fresh Funding and Clinical Progress

July 04, 2025 02:14 PM AEST| By Team Kalkine Media

Highlights,Imugene receives A$5.87M in R&D tax refund for 2024.,Initiates Phase II dosing for colorectal cancer therapy.,Secures key US patent for onCARlytics platform,Imugene Ltd (ASX:IMU) has taken notable strides in advancing its immuno-oncology p...

 CSL and Endeavour Shine as Value Picks in ASX 100 Near Highs

CSL and Endeavour Shine as Value Picks in ASX 100 Near Highs

July 04, 2025 01:25 PM AEST| By Team Kalkine Media

Highlights,CSL Ltd remains focused on growth despite ongoing share price pressure,Endeavour Group continues to maintain market presence through retail network strength,Both companies are listed on the,ASX 100,and trade below recent highs,With the,S&P...

 ASX 300: PTX-100 Advances in Clinical Trials as Prescient Therapeutics Strengthens Biotech Footprint

ASX 300: PTX-100 Advances in Clinical Trials as Prescient Therapeutics Strengthens Biotech Footprint

July 04, 2025 01:21 PM AEST| By Team Kalkine Media

Highlights,Prescient Therapeutics progresses PTX-100 into Phase 2a trials following favourable outcomes in early-stage testing,The company receives US FDA orphan drug and fast track designations for CTCL treatment,PTX-100 shows encouraging tolerance...

 CSL’s Growth Outlook Amid Share Price Pressure: A Deep Dive into the ASX Giant

CSL’s Growth Outlook Amid Share Price Pressure: A Deep Dive into the ASX Giant

July 04, 2025 10:55 AM AEST| By Team Kalkine Media

Highlights,CSL (CSL) has seen a notable share price dip in 2025,Consistent financial growth across revenue, margin, and profitability,Maintains strong positioning among ASX 100 companies,CSL Limited (ASX:CSL), one of the major players in Australia’s...

 ASX 200 | Pro Medicus (ASX:PME) Soars on US Imaging Contracts

ASX 200 | Pro Medicus (ASX:PME) Soars on US Imaging Contracts

July 03, 2025 04:15 PM AEST| By Team Kalkine Media

Highlights,Pro Medicus secures a decade-long imaging contract with US-based UCHealth,Renewal of FMOLHS deal includes new cloud-based imaging deployment,Company reinforces growth in enterprise-wide digital health platforms,Healthcare technology compan...

 Prescient Therapeutics Launches Funding Round to Advance Cancer Therapy Trials

Prescient Therapeutics Launches Funding Round to Advance Cancer Therapy Trials

July 02, 2025 04:11 PM AEST| By Team Kalkine Media

Highlights,Prescient Therapeutics launches SPP to fund Phase 2 trials,PTX-100 targets rare lymphoma with regulatory support,Shares offered at a discounted 4 cents each,Prescient Therapeutics (ASX:PTX) has officially launched a Share Purchase Plan (SP...

 Prescient Therapeutics Opens A$7M Share Plan to Accelerate Cancer Therapy Trials

Prescient Therapeutics Opens A$7M Share Plan to Accelerate Cancer Therapy Trials

July 02, 2025 03:53 PM AEST| By Team Kalkine Media

Highlights,Prescient (ASX:PTX) launches A$7M Share Purchase Plan,Funds directed toward Phase 2 trials of targeted cancer therapy PTX-100,PTX-100 holds Orphan Drug and Fast Track status from US FDA,Prescient Therapeutics (ASX:PTX) has initiated a Shar...

 Pro Medicus (ASX:PME): A Radiology Powerhouse in the ASX200 Spotlight

Pro Medicus (ASX:PME): A Radiology Powerhouse in the ASX200 Spotlight

July 02, 2025 10:19 AM AEST| By Team Kalkine Media

Highlights,PME share price rises over 11% in 2025 YTD,Radiology software firm gains traction amid digital healthcare growth,ASX200 stock,showcases,strong revenue momentum,Pro Medicus (ASX:PME) has emerged as one of the notable gainers on the ASX in 2...

 Prescient Therapeutics ASX:PTX Boosts Oncology Pipeline | All Ordinaries

Prescient Therapeutics ASX:PTX Boosts Oncology Pipeline | All Ordinaries

July 01, 2025 09:58 PM AEST| By Team Kalkine Media

Highlights,Prescient Therapeutics launches Share Purchase Plan to fund PTX-100 Phase 2 development,Funds to support regulatory advancement of first-in-class GGT-1 inhibitor,PTX-100 holds Orphan Drug and Fast Track designations from the US FDA,Prescie...

 Prescient Therapeutics (ASX:PTX) Launches SPP to Boost Cancer Therapy Trials | All Ordinaries

Prescient Therapeutics (ASX:PTX) Launches SPP to Boost Cancer Therapy Trials | All Ordinaries

July 01, 2025 01:39 PM AEST| By Team Kalkine Media

Highlights,Prescient Therapeutics opens Share Purchase Plan to support PTX-100 clinical development,Proceeds to fund Phase 2 trials in treating relapsed cutaneous T-cell lymphoma,PTX-100 holds FDA Orphan Drug and Fast Track status for advanced cancer...

 CSL Ltd Shares Lag Behind ASX 200 Despite Sector Standing

CSL Ltd Shares Lag Behind ASX 200 Despite Sector Standing

June 27, 2025 03:16 PM AEST| By Team Kalkine Media

Highlights,CSL Ltd (ASX:CSL) shares trail peers despite strong sector fundamentals,Shareholder returns weighed down by earnings trends and acquisition impacts,Leading broker commentary highlights mixed performance across divisions,CSL Ltd (ASX:CSL),...

 PYC Therapeutics (ASX:PYC) Pushes Forward with Clinical Trials for Rare Genetic Disorder

PYC Therapeutics (ASX:PYC) Pushes Forward with Clinical Trials for Rare Genetic Disorder

June 27, 2025 01:53 PM AEST| By Team Kalkine Media

Highlights,PYC-002 shows potential in addressing root cause of PMS,Preclinical results indicate strong gene expression restoration,Clinical trials set to begin in approximately 12 months,PYC Therapeutics (ASX:PYC), a biotechnology firm developing pre...

 NeuroScientific (ASX:NSB) Secures StemSmart Technology, Charts Fresh Clinical Path

NeuroScientific (ASX:NSB) Secures StemSmart Technology, Charts Fresh Clinical Path

June 27, 2025 01:19 PM AEST| By Team Kalkine Media

Highlights,NeuroScientific Biopharmaceuticals acquires full ownership of Isopogen WA and StemSmart™ technology,Strategic board changes implemented to support future clinical expansion,Promising early results from StemSmart™ therapy for Crohn’s diseas...

 FDA Greenlight Boosts Atmo Biosciences with Game-Changing Gut Health Innovation

FDA Greenlight Boosts Atmo Biosciences with Game-Changing Gut Health Innovation

June 27, 2025 12:36 PM AEST| By Team Kalkine Media

Highlights,Atmo receives FDA clearance for gas-sensing capsule.,Diagnostic device targets gastrointestinal motility disorders.,U.S. commercial launch expected in July 2025.,Atmo Biosciences (ASX:AT1) has achieved a major milestone with the U.S. Food...

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.